The White House finalized agreements with nine major drugmakers to lower Medicaid prices to levels paid by peer nations as part of a most‑favored‑nation (MFN) strategy. Companies named in the agreements include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi. The administration described the move as an end‑of‑year push to deliver lower medicine prices to U.S. payers. Officials said the deals cover a sizable share of Medicaid drug spend and mirror characteristics of prior pricing accords. The announcements underscore the administration’s continued use of negotiated pricing levers and raise questions about future company pricing strategies, Medicaid access and implications for drug revenue forecasts.